We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$561M
Cap. Flow %
15.73%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 0.67%
3 Consumer Discretionary 0.06%
4 Industrials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCM icon
126
HUTCHMED
HCM
$2.13B
$296K 0.01%
10,000
– –
VCEL icon
127
Vericel Corp
VCEL
$2.21B
$271K 0.01%
+27,211
New +$225K
GRCE
128
Grace Therapeutics
GRCE
$46.3M
$190K 0.01%
3,887
– –
SGYP
129
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$183K 0.01%
+100,000
New +$211K
CASI
130
DELISTED
CASI Pharmaceuticals
CASI
$182K 0.01%
4,368
-4,000
-48% -$149K
PTLA
131
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$158K ﹤0.01%
+100,000
New +$4.39M
ONCS
132
DELISTED
OncoSec Medical Incorporated
ONCS
$94K ﹤0.01%
+227
New +$93.1K
BIIB icon
133
CALL
Biogen
BIIB
$32.6B
$11K ﹤0.01%
+50,000
New +$15.5M
CAPR icon
134
Capricor Therapeutics
CAPR
$482M
$5K ﹤0.01%
400
– –
AFMD
135
DELISTED
Affimed
AFMD
– –
-66,821
Closed -$869K
ALGN icon
136
Align Technology
ALGN
$11.3B
– –
-3,448
Closed -$766K
AMGN icon
137
Amgen
AMGN
$239B
– –
-50,000
Closed -$8.7M
BHC icon
138
Bausch Health
BHC
$2.52B
– –
-30,092
Closed -$625K
BLUE
139
DELISTED
bluebird bio
BLUE
– –
-1,112
Closed -$2.56M
CNC icon
140
Centene
CNC
$32.1B
– –
-13,398
Closed -$676K
CRBP icon
141
Corbus Pharmaceuticals
CRBP
$219M
– –
-6,667
Closed -$1.42M
CRIS icon
142
Curis
CRIS
$3.86M
– –
-476
Closed -$666K
EVH icon
143
Evolent Health
EVH
$553M
– –
-50,000
Closed -$615K
EXEL icon
144
Exelixis
EXEL
$14.1B
– –
-46,361
Closed -$1.41M
GMED icon
145
Globus Medical
GMED
$11.1B
– –
-113,100
Closed -$4.65M
LNTH icon
146
Lantheus
LNTH
$6.58B
– –
-53,763
Closed -$1.1M
QTRX icon
147
Quanterix
QTRX
$132M
– –
-169,400
Closed -$3.64M
REGN icon
148
Regeneron Pharmaceuticals
REGN
$85.8B
– –
-20,000
Closed -$6.96M
URGN icon
149
UroGen Pharma
URGN
$2.27B
– –
-199,014
Closed -$7.41M
ZBH icon
150
Zimmer Biomet
ZBH
$19.1B
– –
-206,000
Closed -$24.1M
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.